Know Cancer

or
forgot password

Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples


N/A
N/A
17 Years
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples


OBJECTIVES:

- To evaluate Mer and Axl expression in samples from pediatric patients with acute
myeloid leukemia (AML).

- To determine if abnormal expression of Mer and Axl is associated with poor clinical
characteristics (e.g., induction failure or relapse) of AML in these patients.

OUTLINE: This is a multicenter study.

Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer
and Axl expression by flow cytometry and western blot assays.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of acute myeloid leukemia

- Children Oncology Group (COG) patient samples

PATIENT CHARACTERISTICS:

- Available clinical data

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Expression of Mer and Axl

Safety Issue:

No

Principal Investigator

Kristen M. Eisenman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Colorado, Denver

Authority:

United States: Federal Government

Study ID:

CDR0000671452

NCT ID:

NCT01139333

Start Date:

September 2009

Completion Date:

Related Keywords:

  • Leukemia
  • childhood acute myeloid leukemia/other myeloid malignancies
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location